International Journal of Applied Research
Vol. 2, Issue 12, Part G (2016)
Oral azithromycin as the systemic treatment of choice in the treatment of Meibomian gland disease
To asses the efficacy and safety of oral Azithromycin when compared with oral doxycycline patients with Meibomian Gland Dysfunction (MGD) who has failed to respond to prior conservative management.
Methods: 30 Patient with MGD were randomly assigned to receive either oral 3 days Azithromycin (500mg/ day) or 3 month Doxycycline (100mg/day). There were 20 Females and 10 males average age 45 years (range 20 to 55) They also continued eye lid warming/ cleaning and artificial tears. Symptoms and signs are recorded prior to treatment and at 1 week, and 1 and 2momths after treatment. side effects are recorded and overall clinical improvement was categorised as excellent, good, fair and poor based on clinical features.
Results: Based on clinical observation excellent score was recorded in 20 cases (66.6%) Good in 6 cases (20%) Fair in 3 cases (10%) Poor in 1 case (3.3%).
Conclusion: This short term study proved Oral Azithromycin is a good alternative for MGD as first line systemic therapy.
How to cite this article:
Y Srinivas, M Parni Kumar, NR Bharathi K. Oral azithromycin as the systemic treatment of choice in the treatment of Meibomian gland disease. Int J Appl Res 2016;2(12):443-444.